Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320434 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03320434 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by ORA. The registered enrollment target is 120 participants, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03320434, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG PRT-2761 0.5%
- DRUG PRT-2761 1%
- DRUG Patanol
- DRUG Pred-forte
- DRUG PRT-2761 0%
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2018-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03320434
The ClinicalTrials.gov registry entry for NCT03320434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 5 interventions - of which PRT-2761 0.5% is the first listed.
NCT03320434 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03320434 about?
NCT03320434 is a clinical study titled "Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis". To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
What is the current status of trial NCT03320434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-10-13. Estimated completion is 2018-02-18.
What conditions does trial NCT03320434 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT03320434?
The interventions under investigation include: PRT-2761 0.5% (DRUG), PRT-2761 1% (DRUG), Patanol (DRUG), Pred-forte (DRUG), PRT-2761 0% (DRUG).
Who is sponsoring clinical trial NCT03320434?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03320434 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.